X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14) 14
female (10) 10
index medicus (10) 10
male (8) 8
aged (7) 7
middle aged (7) 7
care and treatment (6) 6
adult (4) 4
analysis (4) 4
europe (4) 4
mortality (4) 4
surgery (4) 4
treatment outcome (4) 4
abridged index medicus (3) 3
chemotherapy (3) 3
clinical trials (3) 3
diseases (3) 3
hematology, oncology and palliative medicine (3) 3
mutation (3) 3
oncology (3) 3
patients (3) 3
proportional hazards models (3) 3
research (3) 3
therapy (3) 3
adults (2) 2
aged, 80 and over (2) 2
anatomy (2) 2
anesthesia (2) 2
anesthesiology (2) 2
antineoplastic agents - therapeutic use (2) 2
cardiovascular disease (2) 2
chemistry, physical and theoretical (2) 2
clinical medicine (2) 2
cohort studies (2) 2
complications (2) 2
dictionaries (2) 2
disease-free survival (2) 2
double-blind method (2) 2
electrolyte solutions (2) 2
electrolytes (2) 2
electronic books (2) 2
encyclopedias (2) 2
gene mutations (2) 2
genetic aspects (2) 2
genetic research (2) 2
genome, viral (2) 2
health (2) 2
health aspects (2) 2
heart attacks (2) 2
hospitals (2) 2
kaplan-meier estimate (2) 2
klinisk medicin (2) 2
management (2) 2
medical and health sciences (2) 2
medical colleges (2) 2
medicin och hälsovetenskap (2) 2
medicine, general & internal (2) 2
methods (2) 2
multicenter (2) 2
mutations (2) 2
neoplasm recurrence, local - drug therapy (2) 2
obesity (2) 2
open-label (2) 2
operative/mortality (2) 2
outcomes (2) 2
ovarian cancer (2) 2
ovarian neoplasms - drug therapy (2) 2
patient outcomes (2) 2
pediatrics (2) 2
phthalazines - adverse effects (2) 2
phthalazines - therapeutic use (2) 2
piperazines - adverse effects (2) 2
piperazines - therapeutic use (2) 2
population (2) 2
postoperative care/methods (2) 2
postoperative care/statistics and numerical data (2) 2
relapse (2) 2
risk factors (2) 2
rna, viral - genetics (2) 2
rotavirus - genetics (2) 2
social aspects (2) 2
studies (2) 2
surgical procedures (2) 2
transcription, genetic - genetics (2) 2
united kingdom - epidemiology (2) 2
united states (2) 2
11 card11 (1) 1
1975 (1) 1
20040723113306.0 (1) 1
3-dimensional structure (1) 1
5-year follow-up (1) 1
539.53 (1) 1
541.1 (1) 1
621.891 (1) 1
621.892 (1) 1
[ sdv ] life sciences [q-bio] (1) 1
aa-p.012 (1) 1
abdomen (1) 1
abdominal adiposity (1) 1
accreditation (1) 1
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Engineering & Comp. Sci. - Stacks (4) 4
Gerstein Science - Stacks (4) 4
Robarts - Stacks (4) 4
Collection Dvlpm't (Acquisitions) - Closed Orders (3) 3
Earth Sciences (Noranda) - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Faculty of Information - Stacks (1) 1
New College (Ivey) - Stacks (1) 1
Online Resources - Online (1) 1
Robarts - Reference (1) 1
Royal Ontario Museum - Stacks (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
UTL at Downsview - May be requested (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 11, pp. 1579 - 1589
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 8, pp. 852 - 861
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 733 - 740
Summary Background Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has... 
Hematology, Oncology and Palliative Medicine | CELL LUNG-CANCER | TRIAL | KINASE KINASE-1/2 INHIBITOR | MULTICENTER | ONCOLOGY | ORAL MEK INHIBITOR | IMPROVED SURVIVAL | INHIBITOR AZD6244 ARRY-142886 | OPEN-LABEL | MUTATIONS | VEMURAFENIB | Dacarbazine - adverse effects | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents, Alkylating - administration & dosage | Skin Neoplasms - enzymology | Benzimidazoles - administration & dosage | Time Factors | DNA Mutational Analysis | Brazil | Proto-Oncogene Proteins B-raf - metabolism | Dacarbazine - administration & dosage | Genetic Predisposition to Disease | Neoplasms, Unknown Primary - genetics | Europe | Logistic Models | Antineoplastic Agents, Alkylating - therapeutic use | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Mutation | Antineoplastic Agents, Alkylating - adverse effects | Melanoma - mortality | Dacarbazine - therapeutic use | United States | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Melanoma - enzymology | Neoplasms, Unknown Primary - enzymology | Melanoma - genetics | Skin Neoplasms - mortality | Adult | Female | Skin Neoplasms - pathology | Neoplasms, Unknown Primary - drug therapy | Double-Blind Method | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Neoplasms, Unknown Primary - mortality | Melanoma - secondary | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Aged | Neoplasms, Unknown Primary - pathology | Care and treatment | Chemotherapy | Gene mutations | Analysis | Melanoma | Metastasis | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9670, pp. 1190 - 1197
Journal Article
by Devereaux, P.J and Devereaux, P J and Duceppe, Emmanuelle and Guyatt, Gordon and Tandon, Vikas and Rodseth, Reitze and Biccard, Bruce M and Xavier, Denis and Szczeklik, Wojciech and Meyhoff, Christian S and Vincent, Jessica and Franzosi, Maria Grazia and Srinathan, Sadeesh K and Erb, Jason and Magloire, Patrick and Neary, John and Rao, Mangala and Rahate, Prashant V and Rahate, Prashant and Chaudhry, Navneet and Chaudhry, Navneet K and Mayosi, Bongani and Mayosi, Bogani and de Nadal, Miriam and Iglesias, Pilar Paniagua and Berwanger, Otavio and Villar, Juan Carlos and Botto, Fernando and Eikelboom, John and Eikelboom, John W and Sessler, Daniel I and Kearon, Clive and Pettit, Shirley and Sharma, Mukul and Sharma, Ambika and Sharma, Mike and Connolly, Stuart and Connolly, Stuart J and Bangdiwala, Shrikant I and Rao-Melacini, Purnima and Hoeft, Andreas and Yusuf, Salim and Pogue, Janice and Di Diodato, Sara and Gasic, Zora and Mastrangelo, Louise J and Molnar, Sarah H and Swanson, Jennifer L and Tosh, Makayla L and Wells, Jennifer R and Wells, George A and Diaz, Rafael and Chow, Clara K and Gonzales, Beatriz and Vásquez, Skarlet and Jansky, Petr and Dušek, Radovan and Coriat, Pierre and Wittmann, Maria and Yonga, Gerald and Mathur, Nandini and Seletti, Elena and Malaga, German and Tumanan-Mendoza, Bernadette A and Tagle, Maria Pamela A and Alonso-Coello, Pablo and Popova, Ekaterine and Shields, Martin O and Shields, Martin and Le Manach, Yannick and Moayyedi, Paul and van Zanten, Sander and Fleischmann, Edith and Garg, Amit and Karaye, Kamilu and McFalls, Edward and Sigamani, Alben and Belley-Côté, Emilie and Biedroń, Grzegorz and Borges, Flavia and Frosi Stella, Steffan and Haarmark Nielsen, Christian and Leong, Darryl P and Spence, Jessica and Tran, Allen and Wawrzycka-Adamczyk, Katarzyna and Yang, Stephen S and Yung, Terence and Wyse, D. George and Cheng, Davy and Johnstone, David E and Joseph, Philip and Patel, Ameen and Gregus, Krysten and Lawrence, Kelly and Doharris, Lindsay and Conen, David and Cheung, Jason and Douketis, Jim and Wright, Douglas and ... and MANAGE Investigators
The Lancet, ISSN 0140-6736, 06/2018, Volume 391, Issue 10137, pp. 2325 - 2334
Myocardial injury after non-cardiac surgery (MINS) increases the risk of cardiovascular events and deaths, which anticoagulation therapy could prevent.... 
DEFINITION | MORTALITY | MEDICINE, GENERAL & INTERNAL | THERAPY | EVENTS | RIVAROXABAN | DOUBLE-BLIND | ELEVATION | ACUTE CORONARY SYNDROMES | ASPIRIN | Troponin - drug effects | Dabigatran - adverse effects | Myocardial Infarction - epidemiology | Myocardial Infarction - mortality | Dabigatran - administration & dosage | Humans | Stroke - complications | Male | Hemorrhage - prevention & control | Peripheral Arterial Disease - complications | Venous Thromboembolism - drug therapy | Antithrombins - pharmacology | Venous Thromboembolism - prevention & control | Aged, 80 and over | Female | Dabigatran - pharmacology | Troponin - metabolism | Omeprazole - therapeutic use | Stroke - prevention & control | Placebo Effect | Omeprazole - administration & dosage | Perioperative Period - mortality | Hemorrhage - complications | Peripheral Arterial Disease - drug therapy | Treatment Outcome | Stroke - drug therapy | Proton Pump Inhibitors - therapeutic use | Peripheral Arterial Disease - prevention & control | Thrombosis - pathology | Hemorrhage - drug therapy | Myocardial Infarction - drug therapy | Aged | Clinical trials | Anesthesia | Care and treatment | Analysis | Cardiac patients | Heart | Myocardial infarction | Cardiac arrhythmia | Heart attacks | Embolisms | Heart surgery | Risk | Cardiovascular disease | Family medical history | Bleeding | Randomization | Motivation | Safety engineering | Surgery | Amputation | Safety | Thromboembolism | Heart diseases | Anticoagulants | Cerebral infarction | Stroke | Aspirin | Complications | Mortality | Health risks | Patients | Thrombosis | Omeprazole | Sepsis | Infarction | Adults | Cardiovascular diseases | Health risk assessment | Factorial design
Journal Article
by Kahan, Brennan C and Koulenti, Desponia and Arvaniti, Kostoula and Beavis, Vanessa and Campbell, Douglas and Chan, Matthew and Moreno, Rui and Pearse, Rupert M and Beattie, Scott and Clavien, Pierre-Alain and Demartines, Nicolas and Fleisher, Lee A and Grocott, Mike and Haddow, James and Hoeft, Aneas and Holt, Peter and Pritchard, Naomi and Rhodes, Anew and Wijeysundera, Duminda and Wilson, Matt and Ahmed, Tahania and Everingham, Kirsty and Hewson, Russell and Januszewska, Marta and Phull, Mandeep-Kaur and Halliwell, Richard and Shulman, Mark and Myles, Paul and Schmid, Werner and Hiesmayr, Michael and Wouters, Patrick and de Hert, Stefan and Lobo, Suzana and Fang, Xiangming and Rasmussen, Lars and Futier, Emmanuel and Biais, Matthieu and Venara, Aurélien and Slim, Karem and Sander, Michael and Koulenti, Despoina and Chan, Mathew and Kulkarni, Atul and Chana, Susilo and Tantri, Aida and Geddoa, Emad and Abbas, Muntadhar and Della Rocca, Giorgio and Sivasakthi, Datin and Mansor, Marzida and Luna, Pastor and Bouwman, Arthur and Buhre, Wolfgang and Short, Tim and Osinaike, Tunde and Matos, Ricardo and Grigoras, Ioana and Kirov, Mikhail and Protsenko, Denis and Biccard, Bruce and Aldecoa, Cesar and Chew, Michelle and Hofer, Christoph and Hubner, Martin and Ditai, James and Szakmany, Tamas and Fleisher, Lee and Ferguson, Marissa and MacMahon, Michael and Cherian, Ritchie and Currow, Helen and Kanathiban, Kathirgamanathan and Gillespie, David and Pathmanathan, Edward and Phillips, Katherine and Reynolds, Jenifer and Rowley, Joanne and Douglas, Jeanene and Kerridge, Ross and Garg, Sameer and Bennett, Michael and Jain, Megha and Alcock, David and Terblanche, Nico and Cotter, Rochelle and Leslie, Kate and Stewart, Marcelle and Zingerle, Nicolette and Clyde, Antony and Hambidge, Oliver and Rehak, Adam and Cotterell, Sharon and Binh Quan Huynh, Wilson and McCulloch, Timothy and Ben-Menachem, Erez and Egan, Thomas and Cope, Jennifer and Fellinger, Paul and Haselberger, Simone and Holaubek, Caroline and ... and ISOS Grp and International Surgical Outcomes Study (ISOS) group and The International Surgical Outcomes Study (ISOS) group
Intensive care medicine, ISSN 0342-4642, 2017, Volume 43, Issue 7, pp. 971 - 979
Journal Article